Why Is GLAUKOS CORP (GKOS) Stock Up Today?

Glaukos Corp (GKOS) shares surged 33.65% to $242.48, marking a significant jump from its previous trading levels. The primary driver was a strong quarterly earnings report where revenue exceeded consensus estimates, prompting immediate positive reactions from analysts and investors.

What Happened

The stock’s rally was fueled by Glaukos setting a $1 billion sales goal for 2027, a target that some observers suggest may be conservative given the performance of its newer product launches. The company’s two newer launches are currently carrying the business, contributing to a 41.5% year-over-year increase in revenue. In response to the results, several firms adjusted their outlooks. H.C. Wainwright raised its price target to $248 from $195 while maintaining a Buy rating. Piper Sandler also raised its price target, citing the strength of the Epioxa product. Citigroup and Truist Securities both maintained Buy ratings, raising their respective price targets to $247 and $255. The move pushed the stock to a record close, with 29 stories published across 11 sources in the last 36 hours highlighting the momentum.

What The Data Shows

Intraday trading volume catapulted to over 3.4 million shares, a sharp increase from the daily average of approximately 888,000. The stock printed 41 fresh 52-week highs and one fresh 52-week low on October 29, 2026. Over the last eight sessions, the stock had already moved up 38.1%, rising from $173.43 to $239.47 before today’s surge. The company remains unprofitable with a trailing twelve-month EPS of negative $3.25 and a net margin of negative 30.7%, yet its market cap stands at $10.7 billion. Insider activity has been predominantly selling, with eight sales totaling $18.2 million in the last 90 days, including recent transactions by Chief Development Officer Tomas Navratil. Congressional disclosures show one buy and one sell in the same period, with the most recent filing on September 22, 2026.

What To Watch

With the stock now trading well above its previous 52-week high of $191.62, attention will turn to how the market digests the new 2027 sales target. Investors will monitor whether the current valuation supports the continued growth trajectory of the newer product lines and how the company manages its profitability metrics in the coming quarters.